Kamada Ltd
Officers & Directors
Executive Leadership Team: - Amir London, Chief Executive Officer - Amir Blatt, Chief Financial Officer - Gil Efron, Chief Operating Officer - Michal Eldar-Finkelman, Chief Scientific Officer - Udi Gilboa, Vice President, Commercial Board of Directors: - Dr. David Tsur, Chairman of the Board - Amir London, Director - Amir Blatt, Director - Prof. Yigal Burstein, External Director - Dr. Nir Yariv, External Director - Dr
Kamada Ltd currently has 393 employees.
News about Kamada Ltd Key Personnel |
Kamada Projects Continued Profitable Growth Ahead: 2024 Financial Guidance and Ambitious Plans for 2025 Kamada Projects Continued Profitable Growth Ahead: 2024 Financial Guidance and Ambitious Plans for 2025Kamada Ltd. a biopharmaceutical powerhouse hailing from Rehovot, Israel, has set strong financial expectations for 2024, while revealing an optimistic outlook for 2025. As a key player in the development of medicines targeting rare and serious health conditions, Kamada s financial guidance shines a light on its robust commercial infrastructure and zeal for innovation. 2024 Financial Guidance: Strong Revenue and EBITDA ExpectationsKamada has confirmed its financial guidance for 2024, expecting to generate ...
|
In a recent letter to shareholders, Kamada Ltd., a global biopharmaceutical company based in Rehovot, Israel, and Hoboken, N.J., addressed the company s financial performance and its future outlook. Amir London, the Chief Executive Officer, discussed the challenges faced by the company and outlined its plans moving forward.
One of the key points highlighted in the letter was Kamada Ltd. s recorded net loss of $2 million during the 12 months ending in the fourth quarter of 2022. This resulted in a negative return on assets (ROA) of -1.32%, which raises concerns about the company s profitability. It is important to note that this negative ROA suggests that the company s assets generated lower profits ...
|
|
